Honkanen et al. found that, in patients with NSCLC, HER2 modulates the CSLC phenotype in ALK-translocated lung cancers, and this modulation is primarily orchestrated by HER2/HER3 heterodimers [36]. The gene discussed is ERBB3; the disease is lung cancer.